Literature DB >> 6895227

Suppressive effect of 1,25-dihydroxyvitamin D3 on circulating parathyroid hormone in acute renal failure.

S Madsen, K Olgaard, J Ladefoged.   

Abstract

To elucidate whether the kidney hormone 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3) directly feedback regulates the secretion of parathyroid hormone (PTH), 10 patients with acute oliguric renal failure were studied. Serum ionized calcium (Ca++) was kept constant and subnormal by continuous peritoneal dialysis with low Ca++ dialysis fluid. In the control period (24 h), PTH was found to be constantly increased. In the treatment period (30 h), five patients received 250 ng 1,25-(OH)2D3 iv every 6 h, while five comparable patients served as controls. A significant suppression of PTH-levels was observed in the treatment group after a lag-period of 12-18 h during stable low Ca++. In the control group, PTH remained constantly increased throughout the trial. Since Ca++ was kept constant by the dialysis procedure, the observed reduction of PTH-levels cannot be explained by the calcemic effect of 1,25-(OH)2D3. The data suggest that 1,25-(OH)2D3 directly feedback regulates PTH secretion in humans with normal parathyroid glands.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6895227     DOI: 10.1210/jcem-53-4-823

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Efficacy of calcium carbonate and low-dose vitamin D/1,25(OH)2D3 in reducing the risk of developing renal osteodystrophy in children on continuous ambulatory peritoneal dialysis.

Authors:  H Jüppner; P F Hoyer; K Latta; L Winkler; G Offner; J Brodehl
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

2.  Parathyroid hormone suppression by intravenous 1,25-dihydroxyvitamin D. A role for increased sensitivity to calcium.

Authors:  J A Delmez; C Tindira; P Grooms; A Dusso; D W Windus; E Slatopolsky
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

3.  Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure.

Authors:  S Lopez-Hilker; T Galceran; Y L Chan; N Rapp; K J Martin; E Slatopolsky
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

4.  Respiratory alkalosis and reduced plasmatic concentration of ionized calcium in rats treated with 1,25 dihydroxycholecalciferol.

Authors:  M E Locatto; M C Fernandez; D A Caferra; M C Gimenez; M C Vidal; R C Puche
Journal:  Calcif Tissue Int       Date:  1984-09       Impact factor: 4.333

5.  Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.

Authors:  E Slatopolsky; C Weerts; J Thielan; R Horst; H Harter; K J Martin
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

6.  Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.

Authors:  A A Portale; B E Booth; B P Halloran; R C Morris
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

7.  Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat.

Authors:  J Silver; T Naveh-Many; H Mayer; H J Schmelzer; M M Popovtzer
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

8.  FGF-23 and PTH levels in patients with acute kidney injury: A cross-sectional case series study.

Authors:  Maryann Zhang; Raymond Hsu; Chi-Yuan Hsu; Kristina Kordesch; Erica Nicasio; Alfredo Cortez; Ian McAlpine; Sandra Brady; Hanjing Zhuo; Kirsten N Kangelaris; John Stein; Carolyn S Calfee; Kathleen D Liu
Journal:  Ann Intensive Care       Date:  2011-06-14       Impact factor: 6.925

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.